The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

By R. Pertwee. British Journal of Pharmacology, 2008

733 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Genomic and Chemical Diversity in Cannabis (2015, background): “In contrast with THC, which acts as a partial agonist of the CB1 and CB2 receptors, CBD does not have as strong psychoactive properties, and instead has antagonist activity on agonists of the CB1- and CB2-receptors (34).”
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology (2010, background): “The widely distributed brain regions where D-9-THC and CBD had opposite effects is also consistent with the distribution of CB1 receptors in the brain (Elphick and Egertova, 2001) and evidence that they may have opposite effects on these receptors (Pertwee, 2008).”
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (2010, background): “…nonclassical, aminoal-CANNABINOID RECEPTORS AND THEIR LIGANDS 591 a t A SP ET J ou r n a l s on F e b r u a r y 4 , 2024 ph a r m r e v . a s p e tj ou r n a l s . o r g D o w n l o a d e d fr o m kylindole, and eicosanoid (for review, see Pertwee, 1999, 2005a, 2008a,b; Howlett et al., 2002).”